Products & Services · Accrued and other liabilities
Axatilimab - Commercialization Activities — Accrued and other liabilities
Incyte Axatilimab - Commercialization Activities — Accrued and other liabilities decreased by 18.5% to $22.50M in Q1 2026 compared to the prior quarter.
Analysis
StatementSegment
CategoryEfficiency
SignalContext dependent
VolatilityModerate
First reportedQ4 2025
Last reportedQ1 2026Apr 28, 2026
Rolls up toAccrued Expenses
How to read this metric
An increase suggests rising commercial activity or deferred payment obligations for marketing and distribution, while a decrease may indicate the settlement of launch-related costs or a reduction in commercial support intensity.
Detailed definition
This metric represents the total outstanding financial obligations and short-term liabilities specifically associated wi...
Peer comparison
Similar to 'Accrued Marketing and Launch Expenses' or 'Commercialization-related Liabilities' found in other biopharmaceutical companies during the initial product rollout phase.
Metric ID:
incy_segment_axatilimab_commercialization_activities_accrued_and_other_liabilitiesHistorical Data
2 periods
| Q4 '25 | Q1 '26 | |
|---|---|---|
| Value | $27.60M | $22.50M |
| QoQ Change | — | -18.5% |
Range$22.50M – $27.60M
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Incyte's axatilimab - commercialization activities — accrued and other liabilities?
- Incyte (INCY) reported axatilimab - commercialization activities — accrued and other liabilities of $22.50M in Q1 2026.
- What does axatilimab - commercialization activities — accrued and other liabilities mean?
- The total unpaid expenses and short-term financial obligations related to the commercial launch and marketing of the drug Axatilimab.